Combination Drugs: Adding Up the Opportunities - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Combination Drugs: Adding Up the Opportunities
Fixed-dose combination drug therapies give rise to innovation in solid-dosage formulations and manufacturing.

Pharmaceutical Technology
Volume 36, Issue 10, pp. 40-47, 127


1. Code of Federal Regulations, Title 21, Food and Drugs (Government Printing Office, Washington, DC), Chapter I, Part 3, Subchapter A, Sec. 3.2 (e).

2. FDA, FY 2011 Performance Report to Congress for the Office of Combination Products (Rockville, MD).

3. FDA, "Frequently Asked Questions About Combination Products" (Rockville, MD),, accessed Sept. 15, 2012.

4. Code of Federal Regulations, Title 21, Food and Drugs (Government Printing Office, Washington, DC) Chapter 1, Part 300, Subpart B, Sec. 300.50.

5. FDA, FDA Approved Drugs, Drugs@FDA, accessed Sept. 15, 2012.

6. A. Kane, D. Monterroza, and C. Salazar, "Unlocking the Power of New Softgel Technology for Multiple Formulations" Webcast, Pharm. Technol.,, accessed Sept. 15, 2012.

7. FDA, Label for Janumet XR (Rockville, MD, 2012).

8. FDA, Label for Juvisync (Rockville, MD, 2011).

9. FDA, Label for Qsymia (Rockville, MD, 2012).

10. FDA, Label for Jalyn (Rockville, MD, 2010).

11. FDA,Label for Suboxone Sublingual Film (Rockville, MD, 2010).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here